PT Industri Jamu Sido Muncul stock (ID1000126402): Profit plunges in Q1 2026 as sales slide

PT Industri Jamu Sido Muncul reports a 36.8% year?on?year drop in net profit for the first quarter of 2026, with revenue also down nearly 19%.

PT Industri Jamu Sido Muncul has reported a sharp decline in profitability for the first quarter of 2026, as net profit fell 36.8% year?on?year to 147.21 billion Indonesian rupiah, according to data compiled by Databoks on May 9, 2026.Databoks as of 05/09/2026 Revenue for the period also declined by 18.83% year?on?year, underscoring pressure on the herbal?medicine and consumer?health group’s top line.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: PT Industri Jamu dan Farmasi Sido Muncul Tbk
• Sector/industry: Consumer health, herbal medicines, cosmetics and food & beverage
• Headquarters/country: Semarang, Indonesia
• Core markets: Indonesia
• Key revenue drivers: Herbal medicines, over?the?counter health products, cosmetics and functional beverages
• Home exchange/listing venue: Indonesia Stock Exchange (IDX), ticker SIDO
• Trading currency: Indonesian rupiah (IDR)

PT Industri Jamu Sido Muncul: core business model

PT Industri Jamu Sido Muncul is one of Indonesia’s leading producers of traditional herbal medicines, or “jamu,” as well as modern over?the?counter health products, cosmetics and functional foods and beverages.Investing.com as of 05/09/2026 The company markets a broad portfolio of brands that target everyday health concerns such as immunity, digestion, pain relief and general wellness, often positioned as natural or plant?based alternatives to conventional pharmaceuticals.

Founded in 1940 and headquartered in Semarang, Central Java, Sido Muncul has built a nationwide distribution network that reaches pharmacies, drugstores, supermarkets, traditional markets and online channels.Investing.com as of 05/09/2026 Its business model relies heavily on brand recognition, scale in manufacturing and logistics, and the ability to adapt traditional herbal formulations to contemporary consumer preferences, including ready?to?drink formats and lifestyle?oriented packaging.

Main revenue and product drivers for PT Industri Jamu Sido Muncul

The company’s main revenue streams come from herbal medicines and health supplements, followed by cosmetics and functional food and beverage products.Investing.com as of 05/09/2026 Iconic brands such as Tolak Angin, Antangin and other jamu?based lines have long served as volume drivers, while newer product lines aim to capture growth in the wellness and beauty?care segments.

Recent quarterly data show that even with a diversified portfolio, Sido Muncul remains sensitive to changes in consumer spending and competitive dynamics in the Indonesian OTC and herbal?health market.Databoks as of 05/09/2026 The 18.83% year?on?year revenue decline in the first quarter of 2026 suggests that pricing pressure, higher input costs, or softer demand may be weighing on sales, even as the company continues to invest in branding and distribution.

Conclusion

PT Industri Jamu Sido Muncul’s first?quarter 2026 results highlight a challenging environment for the Indonesian herbal?health and consumer?health sector, with both profit and revenue under pressure.Databoks as of 05/09/2026 The 36.8% year?on?year drop in net profit and nearly 19% decline in sales indicate that the company may need to reassess pricing, cost structure and product mix to restore growth momentum.

For US investors, Sido Muncul offers exposure to Indonesia’s large domestic consumer?health market, but also carries typical emerging?market risks such as currency volatility, regulatory shifts and competitive intensity.Investing.com as of 05/09/2026 The stock’s performance will likely depend on how effectively management navigates near?term headwinds while maintaining brand strength and distribution reach in a price?sensitive environment.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.